Researchers Question Russia’s COVID-19 Vaccine Claim
Questions about safety and efficacy surround Putin’s announced approval of a COVID-19 vaccine, with no supporting clinical trial results.
The Aug. 11, 2020 announcement by Russian President Vladimir Putin that the country’s health ministry would approve a COVID-19 vaccine without conducting large-scale clinical trials prompted criticism and alarm from researchers and healthcare groups around the world in various media outlets.
Arguing that the vaccine, Gam-COVID-Vac Lyo, developed by Moscow’s Gamaleya Institute was safe, Putin was quoted on Russian State television saying he knew the vaccine worked effectively, forms strong immunity, and passed all needed checks.
Scientists from other countries noted that the effectiveness of the Russian vaccine cannot be known without independent review of scientific papers on clinical trial results.
The World Health Organization, in a report dated Aug. 10, 2020, listed the Gamaleya vaccine in Phase I trials. ClinicalTrials.gov listed a Phase I study with 38 participants; no results were posted.
Leading vaccine candidates from AstraZeneca, Sinovac, Wuhan Institute of Biological Products/Sinopharm, Moderna, and Pfizer/BioNTech are conducting Phase III trials involving tens of thousands of patients. Another dozen vaccine programs are in Phase I/II trials.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
